Itrocinonide

Itrocinonide (developmental code name D5159) is a synthetic glucocorticoid corticosteroid which was never marketed.[1][2][3]

Itrocinonide
Clinical data
Other namesD5159; 6α,9α-Difluoro-11β,16α,17α-trihydroxy-21-oxa-3-oxoandrosta-1,4-diene-17β-carboxylic acid, ester with ethyl (S)-1-hydroxyethyl carbonate, cyclic (R)-16,17-acetal with butyraldehyde; 6α,9α-Difluoro-11β,16α,17α-trihydroxy-21-oxapregna-1,4-diene-3,20-dione 21-(1-[(ethoxycarbonyl)oxy]ethyl), cyclic (R)-16,17-acetal with butyraldehyde
Drug classCorticosteroid; Glucocorticoid
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H38F2O9
Molar mass568.611 g·mol−1
3D model (JSmol)

References

  1. Nicholas Bodor; Peter Buchwald (29 August 2012). Retrometabolic Drug Design and Targeting. John Wiley & Sons. pp. 193–. ISBN 978-1-118-40776-9.
  2. Robert P. Schleimer (19 April 2016). Inhaled Steroids in Asthma: Optimizing Effects in the Airways. CRC Press. pp. 526–. ISBN 978-0-203-90853-2.
  3. Trevor T. Hansel; Peter J. Barnes (1 January 2001). New Drugs for Asthma, Allergy and COPD. Karger Medical and Scientific Publishers. pp. 95–. ISBN 978-3-8055-6862-3.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.